{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:51:23Z","timestamp":1787863883431,"version":"build-2784847793"},"reference-count":54,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"Key Research & Development Program of Shandong Province","award":["2018GGX109006"],"award-info":[{"award-number":["2018GGX109006"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/14737140.2021.1944110","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T14:51:57Z","timestamp":1624027917000},"page":"917-926","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-3899","authenticated-orcid":false,"given":"Xiuhua","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Linyi Central Hospital, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-2575","authenticated-orcid":false,"given":"Shibin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Linyi Central Hospital, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3979-391X","authenticated-orcid":false,"given":"Kelly Ann","family":"Koral","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-4753","authenticated-orcid":false,"given":"Zhongguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Linyi Central Hospital, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"issue":"1","key":"cit0001","first-page":"e3986","volume":"11","author":"Maqsood MH","year":"2019","journal-title":"Cureus"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0125"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00160"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1159\/000362430"},{"issue":"10","key":"cit0007","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jtho.2020.06.021","volume":"15","author":"Singh S","year":"2020","journal-title":"J Thorac Oncol"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0354"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0025"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.017"},{"key":"cit0013","unstructured":"Hutchison China MediTech Limited. Chi-med announces NDA acceptance in china for surufatinib in non-pancreatic neuroendocrine tumors; [cited 2020 Feb 19]. Available from: https:\/\/www.hutch-med.com\/surufatinib-nda-acceptance\/"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17599"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000846"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i30.6817"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12438"},{"key":"cit0019","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177) Lu-Dotatatefor Midgut neuroendocrine tumors. (1533-4406 (Electronic))."},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1685381"},{"issue":"2","key":"cit0021","first-page":"76","volume":"41","author":"Gastrointestinal Hormone and Neuroendocrine Neoplasm Group, Chinese Society of Gastroenterology, Chinese Medical Association","year":"2021","journal-title":"Chin J Dig"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0056"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0455"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"issue":"16","key":"cit0025","first-page":"1556","volume":"371","author":"Caplin ME","year":"2014","journal-title":"N Engl J Med"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.11.004"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1159\/000500135"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1374"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.01.005"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03368"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0531"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1700951"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113655"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30496-4"},{"key":"cit0035","unstructured":"Hutchison China MediTech Limited. Chi-Med announces the NMPA approval of surufatinib for non-pancreatic neuroendocrine tumors; [cited 2020 Feb 19]. Available from: https:\/\/www.chi-med.com\/wp-content\/uploads\/2020\/12\/a201230.pdf"},{"key":"cit0036","unstructured":"National Library of Medicine. Compound summary of Sulfatinib; [cited 2020 Feb 19]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/52920501"},{"key":"cit0037","unstructured":"Hutchison China MediTech Limited. Package insert of Surufatinib capsules; [cited 2020 Feb 19]. Available from: https:\/\/www.chi-med.com\/sc\/products\/"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.07.010"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.2174\/1389200221666200514131721"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14942"},{"issue":"12","key":"cit0041","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","volume":"25","author":"Xu J","year":"2019","journal-title":"Clin Cancer Res"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30143-3"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00439-0"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30493-9"},{"key":"cit0045","unstructured":"Hutchison China MediTech Limited. Chi-Med initiates rolling submission of NDA to U.S. FDA for surufatinib for the treatment of advanced neuroendocrine tumors; [cited 2020 Feb 19]. Available from: https:\/\/www.chi-med.com\/wp-content\/uploads\/2020\/12\/a201228.pdf"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0453"},{"key":"cit0047","unstructured":"Hutchison China MediTech Limited. HUTCHMED Initiates a Phase Ib\/II Trial of Surufatinib in combination with tislelizumab in patients with advanced solid tumors; [cited 2020 Mar 31]. Available from: https:\/\/www.hutch-med.com\/wp-content\/uploads\/2021\/03\/a210324.pdf"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.94"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1159\/000101798"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001431"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4610"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1693893"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00186-2"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2019.10.002"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1944110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T17:09:07Z","timestamp":1672506547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1944110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/14737140.2021.1944110"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1944110","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}